UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter pylori infection

BMC cancer, 2012-06, Vol.12 (1), p.264-264

2012

Volltextzugriff (PDF)

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study

Journal of clinical oncology, 2021-06, Vol.39 (18_suppl), p.LBA4001-LBA4001

2021

Volltextzugriff (PDF)

Predictors of Survival in Stage IV Metastatic Colorectal Cancer

Anticancer research, 2010-02, Vol.30 (2), p.653-660

2010

Volltextzugriff (PDF)

Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe

Emerging infectious diseases, 2009-06, Vol.15 (6), p.956-959

2009

Volltextzugriff (PDF)

Pituitary Insufficiency after Infectious Meningitis: A Prospective Study

The journal of clinical endocrinology and metabolism, 2010-07, Vol.95 (7), p.3277-3281

2010

Volltextzugriff (PDF)

Modulation of peripheral immune responses by paclitaxel–ifosfamide–cisplatin chemotherapy in advanced non-small-cell lung cancer

Journal of cancer research and clinical oncology, 2013-12, Vol.139 (12), p.1995-2003

2013

Volltextzugriff (PDF)

Ionic Products of Bioactive Glass Dissolution Increase Proliferation of Human Osteoblasts and Induce Insulin-like Growth Factor II mRNA Expression and Protein Synthesis

Biochemical and biophysical research communications, 2000-09, Vol.276 (2), p.461-465

2000

Volltextzugriff (PDF)

Chemotherapy ± Cetuximab Modulates Peripheral Immune Responses in Metastatic Colorectal Cancer

Oncology, 2013-01, Vol.84 (5), p.273-283

2013

Volltextzugriff (PDF)

Prior exposure to chemotherapy: a marker of sensitivity and selection for antiangiogenic therapy in breast cancer?

Expert review of anticancer therapy, 2014-02, Vol.14 (2), p.163-172

2014

Volltextzugriff (PDF)

Pancreatic adenocarcinoma-associated polymyositis treated with corticosteroids along with cancer specific treatment: case report

BMC gastroenterology, 2011-04, Vol.11 (1), p.33-33, Article 33

2011

Volltextzugriff (PDF)

Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis

BMC cancer, 2009-07, Vol.9 (1), p.264-264, Article 264

2009

Volltextzugriff (PDF)

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

The New England journal of medicine, 2022-02, Vol.386 (5), p.449-462

2022

Volltextzugriff (PDF)

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

The lancet oncology, 2019-11, Vol.20 (11), p.1506-1517

2019

Volltextzugriff (PDF)

DNA ploidy: a prognostic factor of response to chemotherapy and survival in metastatic gastric adenocarcinoma

Anticancer research, 2013-03, Vol.33 (3), p.1209-1214

2013

Volltextzugriff (PDF)

Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non-small-cell lung cancer patients

Molecular and clinical oncology, 2016-10, Vol.5 (4), p.440-446

2016

Volltextzugriff (PDF)

Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)

Clinical cancer research, 2022-08, Vol.28 (15), p.3277-3286

2022

Volltextzugriff (PDF)

Hypercalcemia in a patient with cholangiocarcinoma: a case report

International archives of medicine, 2009-10, Vol.2 (1), p.35-35

2009

Volltextzugriff (PDF)

Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4122-4122

2024

Volltextzugriff (PDF)

Mo1250 PATHOLOGICAL COMPLETE RESPONSE (PCR) TO DURVALUMAB PLUS 5-FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND DOCETAXEL (FLOT) IN RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER (GC/GEJC): INTERIM RESULTS OF THE GLOBAL, PHASE 3 MATTERHORN STUDY

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-996-S-996

2024

Volltextzugriff (PDF)

Pregabalin for Opioid-Refractory Pain in a Patient with Ankylosing Spondylitis

Case reports in psychiatry, 2013-01, Vol.2013 (2013), p.1-3

2013

Volltextzugriff (PDF)

CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.TPS193-TPS193

2018

Volltextzugriff (PDF)

Factors Influencing Survival in Stage IV Colorectal Cancer: The Influence of DNA Ploidy

ISRN Gastroenterology, 2013-06, Vol.2013, p.490578-6

2013

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(52)

Publikationsform

Sprache

Englisch
(57)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial

Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter pylori infection

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study

Predictors of Survival in Stage IV Metastatic Colorectal Cancer

Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe

Pituitary Insufficiency after Infectious Meningitis: A Prospective Study

Modulation of peripheral immune responses by paclitaxel–ifosfamide–cisplatin chemotherapy in advanced non-small-cell lung cancer

Ionic Products of Bioactive Glass Dissolution Increase Proliferation of Human Osteoblasts and Induce Insulin-like Growth Factor II mRNA Expression and Protein Synthesis

Chemotherapy ± Cetuximab Modulates Peripheral Immune Responses in Metastatic Colorectal Cancer

Prior exposure to chemotherapy: a marker of sensitivity and selection for antiangiogenic therapy in breast cancer?

Pancreatic adenocarcinoma-associated polymyositis treated with corticosteroids along with cancer specific treatment: case report

Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

DNA ploidy: a prognostic factor of response to chemotherapy and survival in metastatic gastric adenocarcinoma

Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non-small-cell lung cancer patients

Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)

Hypercalcemia in a patient with cholangiocarcinoma: a case report

Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma

Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma

Mo1250 PATHOLOGICAL COMPLETE RESPONSE (PCR) TO DURVALUMAB PLUS 5-FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND DOCETAXEL (FLOT) IN RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER (GC/GEJC): INTERIM RESULTS OF THE GLOBAL, PHASE 3 MATTERHORN STUDY

Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study

Pregabalin for Opioid-Refractory Pain in a Patient with Ankylosing Spondylitis

CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma

Factors Influencing Survival in Stage IV Colorectal Cancer: The Influence of DNA Ploidy

Suchergebnisse filtern